Provided by Tiger Trade Technology Pte. Ltd.

Recursion Pharmaceuticals, Inc.

4.13
+0.10002.48%
Post-market: 4.140.0091+0.22%18:02 EDT
Volume:32.69M
Turnover:136.03M
Market Cap:2.21B
PE:-4.04
High:4.29
Open:4.09
Low:3.98
Close:4.03
52wk High:7.18
52wk Low:2.77
Shares:535.00M
Float Shares:522.33M
Volume Ratio:1.86
T/O Rate:6.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0219
EPS(LYR):-1.4410
ROE:-56.58%
ROA:-27.33%
PB:2.41
PE(LYR):-2.87

Loading ...

Recursion Licenses TxFM RNA Foundation Model to Tempus AI for Oncology Use in USD 12 Million Deal

Reuters
·
Sep 22

Tempus Extends Data Licensing Partnership with Recursion Through November 2029

Reuters
·
Sep 22

Tempus AI, Recursion Extend Data License, Amend Fee Structure

MT Newswires Live
·
Sep 21

Recursion, Tempus Expand AI and RNA Collaboration Agreements

TIPRANKS
·
Sep 21

Tempus AI, Recursion extend data license agreement, enter new license agreement

TIPRANKS
·
Sep 21

Tempus AI, - Recursion Grants Tempus Non-Exclusive Worldwide License to Rna Sequencing Model Txfm

THOMSON REUTERS
·
Sep 21

Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s Rna Foundation Model

THOMSON REUTERS
·
Sep 21

Tempus AI, -Co and Recursion Extend Data Partnership Through November 2029

THOMSON REUTERS
·
Sep 21

Recursion Pharmaceuticals - Enters Amendment to Master Agreement with Tempus on Sept 15, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 21

Recursion Pharmaceuticals - Eliminates Co's Right to Terminate Agreement for Convenience - SEC Filing

THOMSON REUTERS
·
Sep 21

Recursion Pharmaceuticals - Extends Agreement Term from Five to Six Years - SEC Filing

THOMSON REUTERS
·
Sep 21

Recursion’s REC-7735 Trial: Early Precision Oncology Data That Could Move RXRX

TIPRANKS
·
Sep 18

Analysts Have Conflicting Sentiments on These Healthcare Companies: Recursion Pharmaceuticals (RXRX), Teladoc (TDOC) and Oscar Health (OSCR)

TIPRANKS
·
Sep 16

Recursion Pharma CEO Najat Khan Sells 22,408 Shares for $78,822

Reuters
·
Sep 11

Arm's Haas: AI Could Cure Cancer In Our Lifetime — If The Industry Can Build Enough Chips

AI Industry Frontlines
·
Sep 08

Recursion Pharma Director Blake Borgeson Disposes of 30,000 Shares Valued at $100,200

Reuters
·
Sep 03

Nvidia Earnings: Six Signals That Matter for the AI Supply Chain

Earnings Spotlight
·
Aug 26

US Tech Stocks Sell Off Ahead of Nvidia Earnings

Bellwether Stocks Movement
·
Aug 25

Nvidia Faces Major Test This Week as AI Market's Bellwether

Bellwether Stocks Movement
·
Aug 24

Nvidia Q2 FY27 Earnings: Gross Margin, Q3 Guidance in Focus

Bellwether Stocks Movement
·
Aug 21